Lapatinib Monotherapy in Patients with Relapsed, Advanced, or Metastatic Breast Cancer: Efficacy, Safety, and Biomarker Results from Japanese Patients Phase II Studies

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Oct 22

PMID 19844234

Citations 41

Authors

M Toi

H Iwata

Y Fujiwara

Y Ito

S Nakamura

Y Tokuda

T Taguchi

Y Rai

K Aogi

T Arai

J Watanabe

T Wakamatsu

K Katsura

C E Ellis

R C Gagnon

K E Allen

Y Sasaki

S Takashima

Affiliations

Soon will be listed here.

Abstract

Background: HER2-positive metastatic breast cancer (MBC) relapsing after trastuzumab-based therapy may require continued HER2 receptor inhibition to control the disease and preserve the patients' quality-of-life. Efficacy and safety of lapatinib monotherapy was evaluated in Japanese breast cancer patients after trastuzumab-based therapies.

Methods: In studies, EGF100642 and EGF104911 evaluated the efficacy and safety of oral lapatinib given 1500 mg once daily in patients with advanced or MBC. All patients progressed on anthracyclines and taxanes; HER2-positive patients had also progressed on trastuzumab.

Results: For HER2-positive tumours (n=100), objective response rate was 19.0% (95% confidence interval (CI): 11.8-28.1) and clinical benefit rate (CBR) was 25.0% (95% CI: 16.9-34.7). One out of 22 HER2-negative tumour was documented as complete response (n=22). The median time-to-progression (TTP) in the HER2-positive and HER2-negative groups was 13.0 and 8.0 weeks (P=0.007); median overall survival was 58.3 and 40.0 weeks, respectively. The most frequent adverse event was diarrhoea. TTP and CBR were significantly associated with HER2 expression. Patients with tumours harbouring an H1047R PIK3CA mutation or low expression of PTEN derived clinical benefit from lapatinib.

Conclusion: Lapatinib monotherapy had shown anti-tumour activity in Japanese patients with HER2-positive MBC that relapsed after trastuzumab-based therapy, including those with brain metastases. Patients benefiting from lapatinib may have biomarker profiles differing from that reported for trastuzumab.

Citing Articles

Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.

Luo M, Yang J, Schaffer A, Chen C, Liu Y, Chen Y Cancer Discov. 2024; 15(3):511-529.

PMID: 39601595 PMC: 11875934. DOI: 10.1158/2159-8290.CD-24-0827.

Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.

Sun K, Wang X, Zhang H, Lin G, Jiang R Cancer Control. 2024; 31:10732748241278039.

PMID: 39159918 PMC: 11334140. DOI: 10.1177/10732748241278039.

Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature.

de Bernardi A, Bachelot T, Larrouquere L Front Oncol. 2024; 13:1210873.

PMID: 38269026 PMC: 10806069. DOI: 10.3389/fonc.2023.1210873.

Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study.

Qi T, Cao Y Eur J Pharm Sci. 2023; 186:106467.

PMID: 37196833 PMC: 10290754. DOI: 10.1016/j.ejps.2023.106467.

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status.

Irelli A, Parisi A, DOrazio C, Sidoni T, Rotondaro S, Patruno L Cancers (Basel). 2022; 14(12).

PMID: 35740668 PMC: 9220864. DOI: 10.3390/cancers14123003.

References

Burstein H, Storniolo A, Franco S, Forster J, Stein S, Rubin S . A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008; 19(6):1068-74. DOI: 10.1093/annonc/mdm601. View

Arpino G, Wiechmann L, Osborne C, Schiff R . Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008; 29(2):217-33. PMC: 2528847. DOI: 10.1210/er.2006-0045. View

Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J . Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007; 67(3):1170-5. DOI: 10.1158/0008-5472.CAN-06-2101. View

Suter T, Procter M, Van Veldhuisen D, Muscholl M, Bergh J, Carlomagno C . Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007; 25(25):3859-65. DOI: 10.1200/JCO.2006.09.1611. View

Cui X, Schiff R, Arpino G, Osborne C, Lee A . Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005; 23(30):7721-35. DOI: 10.1200/JCO.2005.09.004. View

Kang S, Bader A, Vogt P . Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005; 102(3):802-7. PMC: 545580. DOI: 10.1073/pnas.0408864102. View

Nahta R, Esteva F . HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006; 8(6):215. PMC: 1797036. DOI: 10.1186/bcr1612. View

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

Mukherjee A, Dhadda A, Shehata M, Chan S . Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin Pharmacother. 2007; 8(13):2189-204. DOI: 10.1517/14656566.8.13.2189. View

10.

Xia W, Mullin R, Keith B, Liu L, Ma H, Rusnak D . Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002; 21(41):6255-63. DOI: 10.1038/sj.onc.1205794. View

11.

Nahta R, Yuan L, Du Y, Esteva F . Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007; 6(2):667-74. DOI: 10.1158/1535-7163.MCT-06-0423. View

12.

Geyer C, Forster J, Lindquist D, Chan S, Romieu C, Pienkowski T . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26):2733-43. DOI: 10.1056/NEJMoa064320. View

13.

Guarneri V, Lenihan D, Valero V, Durand J, Broglio K, Hess K . Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006; 24(25):4107-15. DOI: 10.1200/JCO.2005.04.9551. View

14.

Di Leo A, Gomez H, Aziz Z, Zvirbule Z, Bines J, Arbushites M . Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008; 26(34):5544-52. PMC: 2651098. DOI: 10.1200/JCO.2008.16.2578. View

15.

Lin N, Carey L, Liu M, Younger J, Come S, Ewend M . Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008; 26(12):1993-9. PMC: 4524351. DOI: 10.1200/JCO.2007.12.3588. View

16.

Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L . Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17(9):2639-48. DOI: 10.1200/JCO.1999.17.9.2639. View

17.

Blackwell K, Pegram M, Tan-Chiu E, Schwartzberg L, Arbushites M, Maltzman J . Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009; 20(6):1026-31. DOI: 10.1093/annonc/mdn759. View

18.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

19.

Perez E, Koehler M, Byrne J, Preston A, Rappold E, Ewer M . Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008; 83(6):679-86. DOI: 10.4065/83.6.679. View

20.

Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi M, Valabrega G . Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist. 2006; 11(4):318-24. DOI: 10.1634/theoncologist.11-4-318. View